Molecular Diagnostics Lab Software: Custom Build vs Off the Shelf Platforms
Buy the content, and for most laboratories buy the platform too.
On this page
Buy the content, and for most laboratories buy the platform too. If you run two or three fixed, well supported panels at modest volume and do not develop your own assays, SOPHiA GENETICS or PierianDx will beat anything you build, and the money belongs in sequencing capacity. Build once you launch your own assays and vendor turnaround starts setting your launch date.
Where SOPHiA GENETICS and PierianDx genuinely lead
PierianDx is strong on somatic interpretation and the curated knowledge content behind it, which represents years of accumulated curation you would not sensibly recreate. SOPHiA GENETICS bundles pipeline and interpretation together, which is efficient when your assays match their supported content. Fabric Genomics covers germline and rare disease interpretation. Velsera Seven Bridges is strong at pipeline execution and reproducibility. Sunquest Mitogen comes from a laboratory information system lineage and is stronger on specimen handling. Clinisys, Orchard Software, LabWare and STARLIMS hold accessioning and billing at many laboratories already.
Most laboratories should buy, and we would rather lead with that. There is no prize for building a worse knowledge base. If your case mix is stable, your panels are supported, and per case interpretation pricing is not yet a visible line in your cost per test, a purchased platform is cheaper, faster and safer than engineering.
The vendors also carry something specific and expensive: literature curation. Somatic oncology evidence moves weekly, and keeping a classification set current against it is a permanent staffing commitment rather than a project. Licensing curated content as an evidence feed is one of the better bargains in clinical software, and our position is narrower than the usual advice. Buy content. The question on this page is only whether you should also buy the system around it.
Where they stop: the pinned chain from case to classification
Here is the workflow no packaged combination holds. A solid tumour panel signed out in March reports a variant of uncertain significance. Eighteen months later your classification committee reclassifies it as likely pathogenic, and a targeted therapy is now relevant. Which cases reported that variant? What did each report say at the time? Who ordered them? Who decides whether an amended report goes out, and where is the record of the decision not to amend?
Answering that requires a chain nothing in a mixed stack owns: case pinned to assay version, pinned to pipeline version, pinned to the classification set as it stood on the day of sign out, pinned to the ordering provider. Break any link and the query simply cannot run. That same chain is what lets you reproduce a two year old report exactly, and what lets you answer a College of American Pathologists inspector who asks which pipeline version produced a given result.
The wet lab is the second gap and it is where the day actually happens. Between accessioning and a variant call sit extraction, quantification, library preparation, pooling and a sequencing run, each with plate positions, reagent lots, instrument identifiers and quality checkpoints. Interpretation products do not model plates and general laboratory systems do not model them properly, so almost every laboratory runs this part on spreadsheets. That works until a plate map is transposed and two patients' results attach to the wrong specimens. Model the plate as a real object, with specimens occupying positions, positions carrying reagent lots and instrument runs, and every transfer recorded as an operation rather than a copy, and the transposition is either impossible or caught the same hour.
Third, the assay itself is a version. Add a gene, update an aligner or caller, move a quality threshold, narrow a reportable range, and a result from version three is not comparable to one from version five. Packaged products let you change configuration. Fewer of them create a new version and bind every case to the one it ran under, which is the design decision everything else depends on.
The arithmetic: per case interpretation pricing against custom development
Interpretation is priced per case, so the bill grows exactly as your laboratory succeeds. Take your own contract and divide. At $45 per case, 120 cases a month is about $65,000 a year, 300 cases is about $162,000, and 700 cases is about $378,000.
Now the build. A $165,000 first release with $33,000 of migration, then $28,000 a year of support from year two, is roughly $62,000 a year over five years. On per case fees alone that crosses at about 115 cases a month, which is early, and it is precisely why laboratories at that volume overbuild.
Do not act on 115. The fee is not only software, it is curated evidence you would otherwise staff, and replacing curation with engineering is how a laboratory ends up slower and less defensible. The number we would act on is roughly 250 to 300 cases a month combined with a second condition: that you develop your own assays, so vendor support turnaround is setting your launch dates. Volume alone is not the trigger. Volume plus assay autonomy is.
Cost to build a clinical molecular platform
From Digital Heroes delivery experience, a focused first release runs $110,000 to $220,000 and ships in 16 to 22 weeks. That covers accessioning, plate and batch tracking with recorded transfers, assay versioning as a configuration object, pipeline orchestration with sample level quality gates, and report generation. A full platform adding a laboratory owned variant knowledge base, reclassification surveillance, amended reports, per recipient rendering, electronic health record interfaces and payer aware billing handoff runs $300,000 to $700,000 phased over 9 to 15 months.
Data migration runs 10 to 25 percent of the build and clinical laboratories sit at the top if you want reclassification surveillance to reach back over prior years of signed reports. That is usually worth paying for, because a surveillance system that only sees cases from go live forward answers the wrong half of the question. Then year two: 15 to 20 percent of build cost annually for support, new assay onboarding and interface changes.
What else raises the price: the number of distinct assay types, since a somatic solid tumour panel, a germline hereditary panel and a heme malignancy assay have genuinely different reporting and classification models. Instrument and pipeline diversity. Electronic health record interfacing, where discrete structured results are materially harder than sending a rendered document. And accreditation expectations, if your checklist responses require validation documentation for the software itself.
Four conditions under which a laboratory should build
Regulatory fit. Clinical Laboratory Improvement Amendments certification and College of American Pathologists accreditation both turn on reproducibility and traceability. Reproducing a two year old report exactly, naming the pipeline version behind a result, and documenting the decision not to amend a case are all obligations rather than features. If your current stack cannot produce them without a manual query, the gap is compliance, not convenience.
Scale economics. Per case pricing above the crossover, on volume you intend to grow, where the asset accumulating value is your classified variant set and it sits inside somebody else's product.
A workflow that is your competitive advantage. If launching assays quickly is how you win referrals, then assay versioning, pipeline binding and validation records are your product, not overhead. A laboratory whose launch date depends on a vendor's roadmap has outsourced its own differentiation.
Integration sprawl. Count the seams: the laboratory information system, the interpretation product, the pipeline environment, the plate spreadsheets, the report template, the billing handoff, the electronic health record interface. Past three, your errors happen at the seams rather than inside any one tool, and no vendor owns a seam. Laboratories that build almost always describe the same trigger: not a product that failed, but three products that each worked while the handoffs between them quietly did not.
Run the reclassification drill before you commit budget
Run the reclassification drill, and give it two days. Pick a variant your committee has actually reclassified. Ask for the list of every case that reported it, with sign out date, ordering provider, the assay version and pipeline version that produced the result, and what the report said at the time. Then ask a second question: reproduce one of those reports exactly as issued, from source rather than from a stored document.
If both land in two days, your chain is intact and your decision is a contract negotiation about per case pricing. If either is impossible, you have found the build, and it is not an interpretation engine. It is the case chain and the wet lab record underneath it.
Then buy the specification before the software. A paid discovery phase of three to four weeks should end with a signed product requirements document: the assay version object, the plate and transfer model, the quality gate behaviour at sample level rather than run level, the classification record with evidence codes and reviewers, the reclassification workflow including the documented decision not to amend, and acceptance criteria a rival firm could quote against.
Digital Heroes is the wrong firm for you if you want automated variant classification, because that line belongs to a qualified human and any developer eager to cross it is a liability in a regulated laboratory. We contract through India LLP, US LLC and UK LTD entities so intellectual property assigns under your own law, the client owns the repository from the first commit, and you meet the named team before signing. More than fifty specialists, over 2,000 projects, verifiable on Clutch, Trustpilot, Fiverr Vetted Pro and D-U-N-S.
Book a 30-minute call with Digital Heroes and get a written plan and a fixed quote within 48 hours.
The evidence behind this guide
Independent findings on why this investment pays off. Every link goes to the primary source.
- ITIF's 2025 report documents that SMEs operate at roughly 60% of large-firm productivity in advanced economies (citing McKinsey), that CRM platforms deliver a 25-40% improvement in customer retention and a 15-30% boost in sales, and that digital advertising returns about $8 in profit per dollar spent on Google Search and Ads. Source: Information Technology and Innovation Foundation (ITIF) (2025) →
- 48% of private companies cite integration with legacy systems or technical debt as a top obstacle to realizing the full value of their digital and AI investments (behind data quality/availability at 72% and gaps in AI fluency or technology talent/leadership at 53%). Source: Deloitte (2026) →
- SaaS spend averaged $4,830 per employee (up 21.9% year over year), with large enterprises (10,000+ employees) spending roughly $284M annually and running about 660 apps, while organizations wasted an average of $21M annually on unused licenses. Source: Zylo (2025) →
- Brandon Hall Group research on onboarding reports that done well, structured onboarding drives measurable gains in new-hire productivity, employee engagement, and retention; the page notes 41% of organizations experience greater than 5% turnover among new hires. Source: Brandon Hall Group (2024) →
Frequently asked questions
How much does custom NGS laboratory software cost to build?
A focused first release covering accessioning, plate and batch tracking, assay versioning, pipeline orchestration with sample level quality gates and report generation runs $110,000 to $220,000 over 16 to 22 weeks in Digital Heroes delivery experience. A full platform with a laboratory owned knowledge base, reclassification surveillance and health record interfaces runs $300,000 to $700,000. The number of distinct assay types moves the range more than case volume does.
How long before a custom system can sign out its first case?
Sixteen to 22 weeks for one assay end to end, and launching with one rather than three in parallel is consistently the faster path because the second assay costs a fraction of the first. Timeline risk usually comes from instrument metadata access and electronic health record interface scheduling, both of which take weeks of other people's calendars and should be started before engineering kickoff rather than after.
Who owns the variant classifications if a vendor or agency builds the system?
You should own the repository, the cloud infrastructure accounts and your classification data with its full evidence history in exportable form, written into the contract before kickoff. At Digital Heroes the client owns the code from the first commit. This matters more here than in most categories, because the classified variant set gains value every month and is the specific asset that makes changing vendors painful when it lives inside somebody else's platform.
What happens if one sample on a plate fails quality gates?
A system that holds an entire run because of one failed library will be worked around within a week, and the workaround will be a spreadsheet again. Quality gates should hold the sample where the failure is sample level, so ninety five good libraries proceed while one is investigated. Ask any prospective developer this question directly, because the answer tells you whether they have watched a laboratory work or only read about one.
Can we license curated content and build the system around it?
Yes, and that is the split we recommend. Vendor knowledge bases represent real accumulated curation, particularly in somatic oncology, and rebuilding that content is wasteful. What you should stop outsourcing is your own classifications, the evidence codes your committee applied, your interpretation language and the case chain behind every signed report, because those are the assets that make your reports reproducible, defensible and portable.
Should a low volume laboratory build anything at all?
No. Two or three supported panels at modest volume is exactly the shape purchased platforms serve well, and engineering money is better spent on sequencing capacity or a second variant scientist. If one thing genuinely hurts, build only that. A plate and transfer tracker that replaces the wet lab spreadsheet is a small, contained project and it removes the failure mode that keeps laboratory directors awake.
What is the difference between a LIMS and a molecular case system?
A laboratory information management system handles accessioning, specimen handling, billing and general result reporting. A molecular case system pins a case to an assay version, a pipeline version and a classification set, tracks plates and reagent lots through library preparation, and carries a report through sign out and amendment. Trying to make a general system do the second is how laboratories end up with three spreadsheets between accessioning and results.
How do amended reports work when a classification changes?
A classification change should fire an impact assessment listing affected cases with sign out dates and ordering providers. The director then decides per case or per cohort, and the system generates amended reports stating clearly what changed and why, delivered through the same interfaces as the original. Recording the documented decision not to amend matters as much as the amendments themselves, because inspectors ask about both and memory is not evidence.
Where should automation stop in a clinical genomics workflow?
At the classification decision. A model can triage new literature against your variant list and draft a structured evidence summary for a reviewer to accept, edit or reject, which saves genuine curation hours. It should never classify a variant or sign out a report. In a regulated laboratory the decision stays with a qualified human and the system records who decided, when, and on what evidence.
What should we ask a developer before committing budget?
Ask how a two year old report gets reproduced exactly. The answer must involve pinned assay version, pipeline version and classification version. If they talk about storing the rendered document, they have not understood what a clinical laboratory is required to be able to do. Then ask what they have integrated on the instrument side and on the health record side, and listen for whether they describe the awkward parts unprompted.
How do I calculate whether custom software will pay for itself?
Divide the build cost by the monthly benefit, where benefit is hours saved times loaded hourly cost, plus subscription fees replaced, plus any revenue the software unlocks. Three staff saving 10 hours a week each at a $40 loaded rate is about $62,000 a year, which pays back a $60,000 build in roughly 12 months. Across Digital Heroes internal-tool projects, 12 to 24 months is the normal payback range, and anything projecting under 6 months usually means the spreadsheet is hiding costs.
Will custom software work with the tools we already use, like QuickBooks and Stripe?
Yes, and this is one of custom software's genuine advantages: QuickBooks, Stripe, Shopify, and most mainstream business tools publish documented APIs built for exactly this. Expect each standard integration to add one to two weeks of build time, and be suspicious of any quote that lists five integrations without asking what data flows in which direction. The hard cases are legacy systems with no API, which is a question to raise in discovery, not in week nine.
Should I ask for a fixed price or pay the agency hourly?
Fixed price for the first version, hourly or retainer for what comes after launch. A fixed-scope, fixed-price V1 puts the estimation risk on the agency, which is exactly where you want it while trust is unproven; hourly billing on an unscoped greenfield build is a blank check. After launch, flip it, because maintenance and small features arrive unpredictably and fixed-pricing every ticket wastes everyone's time.
Does the tech stack matter, and which one should I ask for?
It matters less than agencies imply, provided it is boring. A mainstream stack, something like React or Next.js on the front end, Node.js or Python behind it, and PostgreSQL for data, means thousands of developers can maintain your system if you ever change vendors. Apply one test: ask how hard it would be to hire a replacement developer for the proposed stack, and walk away from anything built on an agency's in-house framework.
Couldn't I just build my app in Bubble or another no-code tool instead of hiring an agency?
For validating an idea with real users, yes, and we tell clients that honestly. The walls come later: Bubble apps cannot be exported as code to run anywhere else, performance drops on complex data operations, and usage-based pricing climbs as you grow. A meaningful share of Digital Heroes custom builds are rebuilds of no-code MVPs that proved the business worked, which is the system operating as intended: validate cheap, then build the version that scales.
How many people should be working on my software project?
Three to five for a typical focused build: a project lead, one or two engineers, a designer, and part-time QA, which is the standard shape across 2,000+ Digital Heroes projects. Larger platforms justify 6 to 10, but a ten-person team on a small first version usually signals bill padding rather than horsepower. What predicts success is whether a senior engineer is writing your code daily, not the headcount on the proposal.
If an agency builds my software, who actually owns the code?
You should own everything, assigned in writing: the contract transfers full IP to you on final payment, the code lives in your GitHub organization, and hosting runs in cloud accounts you control. The red flag is a proposal that mentions the agency's proprietary platform or framework, which usually means you are renting, not buying. Digital Heroes structures every build this way precisely so a client can fire us and lose nothing but the relationship.
Should we build an MVP first or go straight to the full system?
MVP first, for almost everyone: ship the single workflow that carries the business value in 10 to 16 weeks, learn from real users, then fund phase two from evidence instead of guesses. The caveat is that an MVP is a small version of a well-built system, not a badly built version of a big one; the data model must already support what comes next. An agency that cannot tell you what they deliberately left out of your MVP has not designed one.
What does it cost to keep custom software running after launch?
Budget 15-20% of the original build cost per year, which on a $100,000 system means $15,000 to $20,000 for security patches, dependency updates, bug fixes, and small improvements as real usage reveals what the spec missed. Cloud hosting for a typical business application adds $50 to $300 a month on top. Skipping maintenance does not save the money; in Digital Heroes rescue work, unmaintained systems typically need a far more expensive rebuild within about three years.
Who can build a custom software system?
Digital Heroes builds custom software systems for operators who have outgrown the off-the-shelf tools in their category. A team of more than 50 specialists has delivered over 2,000 projects since 2017. Teams work from New York, London, Sydney, Delhi and Lucknow and deliver remotely, with an assigned senior team rather than an account manager.
Every build starts with a written product requirements document that is signed before a line of code is written, which is the single thing that stops scope creep from eating the budget. Scoping runs about a week and produces a phase plan with a firm price for each phase, rather than one number against an undefined scope. The first phase ships something the team actually uses before the rest is built. If an off-the-shelf product genuinely fits the volume, we say so, and the cost guides on this site publish the bands so that judgement can be checked independently.
What makes Digital Heroes different from other software companies?
Four things that competitors in this bracket cannot simply copy. Digital Heroes runs a YouTube channel with more than 2.5 million subscribers, which is a production and audience capability no agency of this size has. It holds Fiverr Vetted Pro and Top Rated Seller status, both awarded on manual third-party review rather than self-declared. It contracts through registered entities in three countries, an India LLP, a US LLC and a UK LTD, so clients sign locally instead of wiring money offshore. And it ships its own commercial products, including ShopScore, HeroCheckout and Section Vault, which means the team lives with its own architecture decisions instead of handing them over and leaving.
Two more that show up in the work. Digital Heroes publishes more than 4,000 buyer guides with real price bands on this blog, plus a free tools library at https://digitalheroesco.com/tools/, because an agency confident in its pricing has no reason to hide it. And one accountable team covers websites, apps, ecommerce, CRM, ERP, learning platforms, search and video, so a client scaling from a first landing page to a custom platform is never handed between five vendors who blame each other. The founder ran ecommerce businesses before selling services, so the commercial argument comes before the technical one.
How can I check Digital Heroes is legitimate before getting in touch?
Verify it independently rather than taking the site's word for it. The YouTube channel is at https://youtube.com/@DigitalMarketingHeroes, the Fiverr profile at https://www.fiverr.com/shreyanshsin261, and the Upwork profile at https://www.upwork.com/freelancers/shreyanshsingh. Client reviews sit on Clutch at https://clutch.co/profile/digital-heroes-0 and Trustpilot at https://www.trustpilot.com/review/digitalheroes.co.in, and the company page is at https://www.linkedin.com/company/digital-heroes-1/.
Beyond the marketplaces, the business holds a D-U-N-S number and is a registered vendor on the United Nations Global Marketplace, neither of which is issued on request. Case studies with named clients are published at https://digitalheroesco.com/case-studies/. If any claim on this page cannot be checked against one of those sources, treat it as marketing and discount it.
Related guides
More from Carlos.
Account Manager · Beauty & Fashion · New-york · 7 posts on the site
Published · Last updated .
